Tas-205    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy3

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 567 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04587908
(ClinicalTrials.gov)
November 202013/10/2020A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy(REACH-DMD)A Phase 3, Randomized, Placebo-controlled, Double-blind and Open-label, Extension Study of TAS-205 in Patients With Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: TAS-205;Drug: PlaceboTaiho Pharmaceutical Co., Ltd.NULLNot yet recruiting5 YearsN/AMale80Phase 3Japan
2NCT02752048
(ClinicalTrials.gov)
May 20166/4/2016A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyA Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: TAS-205;Drug: PlaceboTaiho Pharmaceutical Co., Ltd.NULLCompleted5 YearsN/AMale36Phase 2Japan
3NCT02246478
(ClinicalTrials.gov)
September 20149/9/2014A Study of TAS-205 for Duchenne Muscular DystrophyA Phase I Study of Single and Multiple Doses of TAS-205 in Patients With Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: TAS-205;Drug: PlaceboTaiho Pharmaceutical Co., Ltd.NULLCompleted5 Years15 YearsMale21Phase 1Japan